Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Earnings for Portage Biotech Inc. (PRTG)
Earnings in 2024 (TTM): $-85,697,000
According to Portage Biotech Inc.'s latest financial reports the company's current earnings (TTM) are $-85,697,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Portage Biotech Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-85,697,000 | $-75,339,000 |
| 2023 | $-122,522,000 | $-104,611,000 |
| 2022 | $-14,817,000 | $-19,169,000 |
| 2021 | $-14,892,000 | $-17,189,000 |
| 2020 | $-5,084,000 | $-7,249,000 |
| 2019 | $-3,594,000 | $-2,635,000 |
| 2018 | $123.74 M | $123.74 M |
| 2017 | $-641,274 | $16.3 M |
| 2016 | $-9,195,389 | $-5,706,189 |
| 2015 | $-4,341,216 | $-3,118,431 |
| 2014 | $-6,626,630 | $-6,304,947 |
| 2013 | $-1,446,578 | $-1,446,578 |
| 2012 | $-3,261,525 | $-2,476,048 |
| 2011 | $-4,286,724 | $-3,836,083 |
| 2010 | $-3,420,602 | $-3,852,505 |
| 2009 | $-594,015 | $-545,985 |
| 2008 | $-625,157 | $-555,522 |
| 2007 | $426.55 K | $-142,201 |
| 2006 | $-9,188,007 | $-4,104,420 |
| 2005 | $-3,718,115 | $-4,180,026 |
| 2004 | $-1,035,293 | $-1,037,933 |
| 2003 | $-207,482 | $-217,582 |
| 2002 | $-830,361 | $-835,742 |
| 2001 | $-1,093,207 | $-1,089,596 |
| 2000 | $ | $-957,259 |
| 1999 | $ | $-316,503 |
| 1998 | $ | $-396,643 |